<p>/PRNewswire/ -- Okami Medical 是一家开创性医疗技术公司，专注于新型血管栓塞解决方案，今天宣布在 ALPHA 注册中招募了第一位患者。该前瞻性多中心注册评估 LOBO™血管闭合系统在多种外周血管疾病患者中的安全性和有效性，包括动脉出血和肺动静脉畸形。</p>
<p>&#34;我们很荣幸能够在 ALPHA 注册中招募第一位患者，&#34;马萨诸塞大学纪念医疗中心的宁城&#34;彼得&#34;李医学博士和尼尔·J·雷斯尼克医学博士表示。&#34;这个案例展示了 LOBO 系统在肺动静脉畸形（PAVM）治疗中的实用性。多个 PAVM 通过 LOBO 治疗，每条供血动脉植入一个设备，且每条血管的过程内闭合在两分钟内完成。这一重要里程碑开启了一项重大努力，以生成有意义的临床证据来支持 LOBO 设备。&#34;</p>
<p>LOBO 设备旨在提供对外周血管的可控机械闭合，适用于广泛的解剖结构。该设备的专有_High Definition_ BRAID 结构优化了可输送性、闭合性和稳定性，使医生能够快速实现可靠的闭合，同时保持程序的高效性。</p>
<p>&#34;LOBO 血管闭合器是一种独特的栓塞系统，能够在多种血管疾病中提供快速且可预测的闭合，&#34;北卡罗来纳大学健康系统的现场研究员尼玛·科卡比医学博士表示。&#34;ALPHA 注册的独特结构能够评估多种临床条件下的不同结果，并能够收集关键的临床见解，帮助医生改善栓塞患者的护理。我们为能够为支持 LOBO 的不断增长的临床证据贡献力量而感到自豪，并继续推动这一疗法向前发展。&#34;</p>
<p>ALPHA 注册是 Okami 更广泛临床战略中的关键一步，旨在提供关于 LOBO 设备在血管栓塞程序中实际使用的强有力证据。该综合注册将作为继续扩展 LOBO 血管闭合系统临床证据的基础，计划在多达 30 个地点招募多达 500 名患者。</p>
<p><strong>关于 Okami Medical</strong></p>
<p>停止血流，恢复生命。这是 Okami Medical, Inc.的使命，这是一家私人持有的医疗设备公司，致力于通过开发创新、多功能和直观的外周血管闭合设备来满足患者和医生不断变化的需求。该公司于 2017 年由 Inceptus Medical 创立，Inceptus Medical 是一家医疗设备孵化器。欲了解更多信息，请访问 www.okamimedical.com。</p>
<p>来源：</p>
<p>Okami Medical, Inc.</p>
<p>949-446-9710</p>
<p>[email protected]</p>
<p>来源 Okami Medical, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1"/></p>

OMED

CS精准医

<p>Okami Medical 宣布已招募首位患者参与 ALPHA 注册，评估 LOBO™ 血管闭塞系统在各种外周血管疾病中的安全性和有效性。LOBO 设备旨在高效地提供对外周血管的控制性闭塞。该注册将招募多达 500 名患者，覆盖 30 个地点，为支持 LOBO 系统在栓塞手术中的应用提供临床证据。此举是 Okami 提升患者护理的创新医疗解决方案战略的一部分</p>

<p>, /PRNewswire/ -- Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO™ Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Okami Medical 是一家开创性医疗技术公司，专注于新型血管栓塞解决方案，今天宣布在 ALPHA 注册中招募了第一位患者。该前瞻性多中心注册评估 LOBO™血管闭合系统在多种外周血管疾病患者中的安全性和有效性，包括动脉出血和肺动静脉畸形。</p>
</div><p>&#34;We are honored to enroll the first patient in the ALPHA Registry,&#34; said Ningcheng &#34;Peter&#34; Li, MD and Neil J. Resnick, MD at UMass Memorial Medical Center. &#34;This case demonstrates the utility of the LOBO system in pulmonary arteriovenous malformation (PAVM) treatment. Multiple PAVMs were treated with LOBO, with one device implanted per feeding artery, and intraprocedural occlusion achieved in under two minutes per vessel. This significant milestone kickstarts a substantial effort to generate meaningful clinical evidence supporting the LOBO device.&#34;</p>
<div class="lb-trans"><p>&#34;我们很荣幸能够在 ALPHA 注册中招募第一位患者，&#34;马萨诸塞大学纪念医疗中心的宁城&#34;彼得&#34;李医学博士和尼尔·J·雷斯尼克医学博士表示。&#34;这个案例展示了 LOBO 系统在肺动静脉畸形（PAVM）治疗中的实用性。多个 PAVM 通过 LOBO 治疗，每条供血动脉植入一个设备，且每条血管的过程内闭合在两分钟内完成。这一重要里程碑开启了一项重大努力，以生成有意义的临床证据来支持 LOBO 设备。&#34;</p>
</div><p>The LOBO device is designed to provide controlled, mechanical occlusion of peripheral vessels across a broad range of anatomies. The device's proprietary <em>HD</em> BRAID construction optimizes deliverability, occlusivity, and stability, enabling physicians to quickly achieve reliable occlusion while maintaining procedural efficiency.</p>
<div class="lb-trans"><p>LOBO 设备旨在提供对外周血管的可控机械闭合，适用于广泛的解剖结构。该设备的专有_High Definition_ BRAID 结构优化了可输送性、闭合性和稳定性，使医生能够快速实现可靠的闭合，同时保持程序的高效性。</p>
</div><p>&#34;The LOBO vascular occluder is a one-of-a-kind embolization system that delivers fast and predictable occlusion across a wide variety of vascular conditions.&#34; said Nima Kokabi, MD, site investigator at UNC Health System. &#34;The ALPHA Registry is uniquely structured to assess distinct outcomes across multiple clinical conditions, with the ability to gather key clinical insights that will help physicians enhance patient care in embolization. We are proud to contribute to the growing body of clinical evidence supporting LOBO and continue to advance this therapy forward.&#34;</p>
<div class="lb-trans"><p>&#34;LOBO 血管闭合器是一种独特的栓塞系统，能够在多种血管疾病中提供快速且可预测的闭合，&#34;北卡罗来纳大学健康系统的现场研究员尼玛·科卡比医学博士表示。&#34;ALPHA 注册的独特结构能够评估多种临床条件下的不同结果，并能够收集关键的临床见解，帮助医生改善栓塞患者的护理。我们为能够为支持 LOBO 的不断增长的临床证据贡献力量而感到自豪，并继续推动这一疗法向前发展。&#34;</p>
</div><p>The ALPHA Registry is a key step in Okami's broader clinical strategy to deliver robust evidence on the real-world use of the LOBO device in vascular embolization procedures. This comprehensive registry will serve as a foundation for the continued expansion of clinical evidence on the LOBO vascular occlusion system with plans to enroll up to 500 patients across up to 30 sites.</p>
<div class="lb-trans"><p>ALPHA 注册是 Okami 更广泛临床战略中的关键一步，旨在提供关于 LOBO 设备在血管栓塞程序中实际使用的强有力证据。该综合注册将作为继续扩展 LOBO 血管闭合系统临床证据的基础，计划在多达 30 个地点招募多达 500 名患者。</p>
</div><p><strong>About Okami Medical</strong></p>
<div class="lb-trans"><p><strong>关于 Okami Medical</strong></p>
</div><p>Stopping flow. Restoring lives. This is the mission of Okami Medical, Inc., a privately held medical device company committed to addressing the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels. The company was created in 2017 by Inceptus Medical, a medical device incubator. For more information, please visit www.okamimedical.com.</p>
<div class="lb-trans"><p>停止血流，恢复生命。这是 Okami Medical, Inc.的使命，这是一家私人持有的医疗设备公司，致力于通过开发创新、多功能和直观的外周血管闭合设备来满足患者和医生不断变化的需求。该公司于 2017 年由 Inceptus Medical 创立，Inceptus Medical 是一家医疗设备孵化器。欲了解更多信息，请访问 www.okamimedical.com。</p>
</div><p>Source:</p>
<div class="lb-trans"><p>来源：</p>
</div><p>Okami Medical, Inc.</p>
<div class="lb-trans"><p>Okami Medical, Inc.</p>
</div><p>949-446-9710</p>
<div class="lb-trans"><p>949-446-9710</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Okami Medical, Inc.</p>
<div class="lb-trans"><p>来源 Okami Medical, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDA3Jk5ld3NJdGVtSWQ9U0YyODg1NSZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MDcxNjA2UFJfTkVXU19VU1BSX19fX19TRjI4ODU1" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF28855&amp;Transmission_Id=202604071606PR_NEWS_USPR_____SF28855&amp;DateId=20260407"/></p>

16:06 ET Okami Medical 宣布首位患者已加入 ALPHA 注册表